About

TRIGR is an emerging biotechnology company in the field of immuno-oncology therapies that was incorporated in April 2018 and managed by biopharmaceuticals industry veterans (Roche, Abraxis, Merck, Sanofi Aventis, Pfizer). TRIGR focuses on clinical development and commercialization of next generation targeted immuno-oncology drugs for the Asian, US and European markets. The Company’s pipeline includes a clinical stage dual-angiogenesis bispecific antibody program (TR009) and pre-clinical dual checkpoint and immune engaging bispecific antibodies targeting 4-1BB, PDL1, BCMA, B7H4 and LAG3.